Liposomal sirolimus

Liposomal sirolimus is a specialized drug formulation that encapsulates sirolimus (also known as rapamycin) within liposomes to enhance its delivery and therapeutic efficacy. This formulation offers several advantages over traditional sirolimus administration, including improved bioavailability and targeted drug delivery. ## Description Liposomal sirolimus is a novel drug delivery system that encapsulates sirolimus within spherical vesicles composed of at least one lipid bilayer[3]. This formulation was developed to overcome limitations of conventional sirolimus administration, such as poor water solubility and systemic side effects[2][3]. Sirolimus is a potent inhibitor of the mammalian target of rapamycin (mTOR) with an IC50 of 0.1 nM in HEK293 cells[7]. It functions by binding to FKBP12 and acting as an allosteric inhibitor of mTORC1[7]. This mechanism gives sirolimus immunosuppressive, anti-inflammatory, anti-fibrotic, anti-proliferative, and anti-angiogenic properties[3]. The liposomal encapsulation of sirolimus provides several advantages: - Extended drug half-life compared to free sirolimus - Reduced toxicity - Improved targeting to specific tissues - Enhanced stability and bioavailability ## Clinical Applications Liposomal sirolimus has been investigated for various therapeutic applications: 1. **Cancer Therapy**: Studies have shown that sirolimus liposome formulations can be used as an alternative treatment for breast cancer compared to free drug preparations[2]. 2. **Ocular Conditions**: - Liposomal sirolimus has been evaluated for treating retinal vascular disorders characterized by pathologic proliferative and angiogenic processes[3]. - Subconjunctival sirolimus-loaded liposomes have demonstrated effectiveness in reducing both signs and symptoms of dry eye in patients with poorly controlled moderate-to-severe dry eye disease[6]. 3. **Facial Angiofibromas in Tuberous Sclerosis**: Topical liposomal rapamycin (sirolimus) has shown effectiveness and safety for the treatment of facial angiofibromas associated with tuberous sclerosis[9]. ## Formulation Characteristics Commercially available liposomal sirolimus formulations typically have the following properties: - Liposome size: 70-120 nm - Lipid molar concentration: approximately 60 mM - Drug concentration: around 3.3 mg/mL - PEGylated liposomal structure for optimal in vivo performance[7] ## Safety Profile The safety profile of liposomal sirolimus appears to be favorable compared to systemic administration of conventional sirolimus. Studies have shown reduced systemic exposure and fewer adverse effects with liposomal formulations[3][6]. However, as with any sirolimus preparation, monitoring for potential immunosuppressive effects may be necessary, especially with long-term use.